Filing Flows › ADC Therapeutics SA (ADCT) › Guidance & outlook
ADC Therapeutics SA (ADCT) guidance and outlook
ADC Therapeutics SA (ADCT) gave its guidance on Oct 13, 2026: Revenue (segment) $21.0M for Q3 2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | Q3 2026 | $21.0M | new |
From the earnings release filed Oct 13, 2026 (8-K on EDGAR).
ADC Therapeutics SA's latest quarter
ADC Therapeutics SA, Q2 2026: revenue $19.2M (+2% year over year), operating margin -132.0%, net loss $16.6M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.
Questions
Did ADC Therapeutics SA raise or lower its guidance?
ADC Therapeutics SA (ADCT) gave its guidance on Oct 13, 2026: Revenue (segment) $21.0M for Q3 2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.